What is the clinical and trial data, including false-positive rates and PPV, supporting the expanded, routine use of cell-free DNA-based NIPT in lower- and average-risk patients?

What is the clinical and trial data, including false-positive rates and PPV, supporting the expanded, routine use of cell-free DNA-based NIPT in lower- and average-risk patients?

What is the clinical and trial data, including false-positive rates and PPV, supporting the expanded, routine use of cell-free DNA-based NIPT in lower- and average-risk patients?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Errol R. Norwitz, MD, PhD, MBA

Errol R. Norwitz, MD, PhD, MBA

Louis E. Phaneuf Professor of Obstetrics & Gynecology
Tufts University School of Medicine
Chairman, Department of Obstetrics & Gynecology
Tufts Medical Center
Boston, MA